Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2024-09-19 Report Publication Anno…
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (3353 characters) and its primary purpose is to announce *when* the company will release its financial results ("NOTICE OF INTERIM RESULTS"). It explicitly states the date the Interim Results will be announced (September 26, 2024) and mentions an associated analyst briefing/webcast. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). The filing uses the RNS format, but RPA is more specific than the general RNS fallback.
2024-09-19 English
Arecor presents positive AT278 data at EASD
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 6615D' and contains contact information for 'RNS, the news service of the London Stock Exchange'. This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is a press release announcing positive Phase I clinical trial data for a drug candidate (AT278) presented at a medical conference (EASD 2024). This type of announcement, which is a general corporate update and does not fit neatly into specific financial reporting categories like 10-K, ER, or IR, is best classified as a general Regulatory Filing or Announcement. Since it is a standard press release format distributed via RNS, 'RNS' is the most appropriate code, as it serves as the general regulatory announcement category.
2024-09-11 English
Arecor announces AT278 presentation at EASD 2024
Regulatory Filings Classification · 99% confidence The document is an official announcement disseminated via RNS (RNS Number: 6089C) on September 3, 2024. The content announces that the company's abstract regarding its AT278 clinical data has been selected for an oral presentation at the European Association for the Study of Diabetes (EASD) 2024 meeting. This is not a full report (like 10-K or IR), nor is it a transcript of a call (CT). It is an announcement about the upcoming presentation of scientific data, which falls under general regulatory announcements or investor relations updates. Since it is a formal announcement distributed through the RNS system detailing an upcoming event/presentation, the most appropriate classification is Regulatory Filings (RNS), as it serves as a general regulatory disclosure that doesn't fit the more specific categories like ER, IP, or AGM-R (which would be materials *from* the AGM). Given the nature of the announcement (a company informing the market about an abstract acceptance for a scientific conference), RNS is the best fit as a general regulatory disclosure.
2024-09-03 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured data fields typical of regulatory filings concerning changes in share ownership thresholds. Specifically, it details the 'Total positions of person(s) subject to the notification obligation' and reports a change in voting rights percentage (from 7.96% to 6.37%). This type of filing, which reports changes in significant share ownership, corresponds directly to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2024-08-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding text mentioning RNS and the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership by an entity ('Oxford Technology 2 VCT Plc'). This type of filing, reporting changes in significant shareholdings (crossing thresholds), directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-08-20 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to voting rights, share thresholds, and notification dates (09/08/24). This structure is characteristic of regulatory filings concerning changes in significant share ownership. The RNS Number and reference to the FCA confirm its regulatory nature. This directly matches the definition for Major Shareholding Notification (MRQ).
2024-08-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.